Lawsuit Intelligencer Vol. I · No. 2 · June 2026

Lawsuit Intelligencer

Editorial analysis of mass torts, product liability, toxic exposure litigation, and the business of plaintiff-side law in the age of AI.

Lawsuit Intelligencer covers the lawsuits, regulations, referral systems, legal marketing practices, and technologies reshaping modern litigation — the questions that don't fit in consumer legal media or law firm marketing.

Recent

  1. ByHeart's Five-Month Sprint to MDL 3178

    A November recall became a centralized federal docket by April — one of the fastest recall-to-MDL runs in recent memory. The hybrid structure, the single-defendant economics, and the first outbreak of its kind make this a different underwriting problem than the latency torts.

    By David Meldofsky · 6 min read

  2. AI Due-Diligence Queries Are Reading Your Firm

    Search Console data across an attorney-run legal publishing network keeps surfacing the same thing: templated, machine-built queries scanning companies for litigation exposure and scanning legal brands for legitimacy. The assistants are checking references before they cite. Most firms have no page that answers.

    By David Meldofsky · 5 min read

  3. Hair Relaxer's Daubert Gate and Intake Economics

    Eleven and a half thousand cases are waiting on one admissibility ruling. The general-causation Daubert fight in MDL 3060 is the binary event that reprices every hair relaxer inventory in the country — and the Acetaminophen MDL is the cautionary tale everyone in the room remembers.

    By David Meldofsky · 6 min read

  4. The Startup Suing Washington Over an AI Kill Switch

    A San Jose legal-tech startup is suing the federal government to reverse the export-control order that switched off Anthropic's Fable 5 and Mythos 5. A plain-language guide to the claims, the government's likely defenses, and the first real test of whether Washington can disable a frontier AI model already in use.

    By David Meldofsky · 8 min read

  5. The Conduit Defense Meets a Sovereign: Fable 5, Garcia, and Section 230

    An export-control directive pulled Claude Fable 5 offline as a controlled capability, not protected speech. What the takedown, the Garcia product ruling, and Anthropic's own call for FAA-style regulation mean for the product-or-content question and the Section 230 defense.

    By David Meldofsky · 9 min read

  6. The Inventory Nobody Knows How to Price: Inside the AI Wrongful Death Docket

    Four case fronts in ten months, all pretrial, and a filing pace that keeps accelerating. How plaintiff firms are building inventory against a docket with no settlement history, no merits ruling, and no consolidation — and what reprices it in the second half of 2026.

    By David Meldofsky · 10 min read

  7. The First AI Infrastructure Class Action: 10,000 Mississippi Residents Take On xAI's Colossus Gas Plant

    A nuisance suit filed this week opens a second litigation front against the same Southaven facility already facing a Clean Air Act citizen suit, a pending preliminary injunction, and possible DOJ intervention. The physical-externalities half of the AI docket has arrived.

    By David Meldofsky · 7 min read

  8. The Fee That Isn’t a Fee

    Private equity’s path into personal injury law rests on a single undefined word. California and Illinois wrote it into their statutes without saying what it means — and no court has decided where a management fee ends and “indirect” fee-sharing begins.

    By David Meldofsky · 7 min read

  9. Federal PFAS Rules Are Contracting. State PFAS Rules Aren't. The Litigation Will Follow the States.

    The 2024 EPA drinking water standards looked like a foundation for the next wave of PFAS litigation. EPA's 2025–2026 rollback collapsed that assumption. What changes for plaintiff lawyers when the federal anchor moves and the state floors don't.

    By David Meldofsky · 8 min read

  10. AI Can Write the Brief. You Still Have to Verify It.

    The sanctions docket is now its own body of law, and almost every entry failed at the same step. A working guide to using generative AI in court filings without ending up in a show-cause order.

    By David Meldofsky · 9 min read

  11. Welcome to Lawsuit Intelligencer

    What this publication is, what it isn't, and why it exists.

    By David Meldofsky · 3 min read

From the Editor, Published Elsewhere

What We Cover

Mass Torts & Product Liability

PFAS, AFFF, talc, pharmaceutical and medical device litigation, MDL practice, and the doctrines moving through them.

The Business of Plaintiff-Side Law

Intake, referral economics, lead generation, legal marketing, AI in legal practice, firm consolidation, and the regulatory environment around all of it.

Regulation That Moves Litigation

Federal and state agency action — EPA, FDA, FCC, state AGs, state bars — analyzed for what it means in court, not what the press release said.